Research Progress on Dual Therapy in Primary Treatment of Helicobacter pylori Infection / 胃肠病学

ABSTRACT

At present, the global prevalence of Helicobacter pylori (Hp) infection is still high. Although bismuth-containing quadruple regimens are recommended by international consensus and guidelines as a first-line treatment for Hp infection, the compliance is decreasing due to more drugs needed and higher adverse events. In recent years, many studies on eradication regimen containing high-dose proton pump inhibitor (PPI) and amoxicillin, a low-resistance and acid-labile antibiotic, demonstrated that the dual therapy could achieve high eradication rate equivalent to the mainstream fist-line therapies and had the advantages of less adverse events, simpler drug composition and higher compliance. However, there are discrepancies in dosage and frequencies of drugs in dual therapies, and cannot reach a unified regimen. This article reviewed all kinds of the dual therapy regimens, which might be helpful for determining the optimal dosage, frequencies, and treatment course, so as to standardize the dual therapy.